Efficacy of thalidomide for a girl with inflammatory calicinosis, a severe complication of juvenile dermatomyosistis by Miyamae, T et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Efficacy of thalidomide for a girl with inflammatory calicinosis, a 
severe complication of juvenile dermatomyosistis
T Miyamae*, M Kikuchi, K Kasai, R Hara, U Kaneko, T Shinoki, T Imagawa, 
M Mori and S Yokota
Address: Department of Pediatrics, Yokohama City University, Yokohama, Japan
* Corresponding author    
Background
Juvenile dermatomyositis (JDM) is a systemic connective
tissue disease characterized by typical skin rash and
chronic muscle inflammation of unknown etiology. Cal-
cinosis is one of the severe complications of JDM. It occurs
in up to 30% of patients and results in major disability.
Case report
A girl, 14 years of age, was diagnosed as having JDM when
she was 4 years old after a few months of increasing leth-
argy, muscle pain, muscle weakness, and rash. Calcinosis
was recognized 18 months after disease onset. During 3
months, clinical manifestations and abnormal laboratory
findings were effectively treated with prednisolone. How-
ever, generalized calcinosis rapidly progressed with high
fever, multiple skin/subcutaneous inflammatory lesions,
and increased level of CRP. Methylprednisolone pulses,
cyclophosphamide, cyclosporine, azathioprine, and mag-
nesium hydroxide/aluminum hydroxide were applied but
failed. Examination of subcutaneous calcium milk
revealed remarkably elevated levels of IL-6, TNF-α, and IL-
1β. Being encouraged by partial effectiveness with etaner-
cept, thalidomide was started when she was 12 years old.
Clinical manifestations were subsided, and inflammatory
markers showed remarkable improvement. However,
recent examination by whole body PET-CT over 15
months thalidomide treatment still demonstrated hot
spots around subcutaneous calcified lesion.
Conclusion
It suggested that thalidomide for calcium milk around the
generalized calcinosis in a JDM patient could be effective
to improve inflammatory manifestations and patient's
QOL. We speculated that subcutaneous pooling of cal-
cium milk may be the cause of inflammation and subse-
quent calcinosis in JDM, and TNF blockade by
thalidomide will be beneficial for inhibiting systemic
spreading of inflammation.
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